761.F PHARMANUTRA S.P.A.
- Market cap
- EUR 806M
- P/E
- 36.8x
- P/B
- 11.22x
- ROE
- 28.5%
- Dividend yield
- 1.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 761.F undervalued?
Graham numberThe Graham number of PHARMANUTRA S.P.A. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PHARMANUTRA S.P.A. fundamental analysis
No fundamental analysis for PHARMANUTRA S.P.A. yet.
PHARMANUTRA S.P.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PHARMANUTRA S.P.A.
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastroi…
Full company profilePHARMANUTRA S.P.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PHARMANUTRA S.P.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 68.8M | 83.4M | 101M | 117M | 133M | 148M |
| Gross Profit | 51.2M | 61.5M | 71.7M | 90.8M | 103M | 111M |
| Operating Income | 19.1M | 23.3M | 23.6M | 28.1M | 30.3M | 31.3M |
| EBITDA | - | 24.6M | 27.2M | 32.2M | 34.3M | 34.7M |
| Net Income | 13.8M | 15.0M | 12.8M | 16.6M | 20.0M | 19.9M |
| EPS | 1.42 | 1.56 | 1.33 | 1.73 | 2.09 | 2.07 |
| Balance Sheet | ||||||
| Total Assets | 71.4M | 100M | 112M | 117M | 125M | 121M |
| Total Liabilities | 26.3M | 49.2M | 58.0M | 55.3M | 54.0M | 51.4M |
| Shareholders' Equity | 45.1M | 50.9M | 54.4M | 62.2M | 71.4M | 69.7M |
| Cash & Short-term Investments | 29.4M | 22.1M | 18.9M | 15.6M | 18.6M | 7.23M |
| Cash Flow | ||||||
| Operating Cash Flow | 20.4M | 17.5M | 12.1M | 20.5M | 19.6M | -1.66M |
| Capital Expenditure | 4.99M | 26.2M | 13.2M | 4.25M | 3.13M | 4.73M |
| Free Cash Flow | 15.4M | -8.69M | -1.16M | 16.3M | 16.4M | -6.38M |
| Ratios | ||||||
| ROE | 30.5% | 29.5% | 23.6% | 26.7% | 28.0% | 28.5% |
| ROA | 19.3% | 15.0% | 11.4% | 14.1% | 16.0% | 16.4% |
| Net Profit Margin | 20.0% | 18.0% | 12.7% | 14.2% | 15.0% | 13.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PHARMANUTRA S.P.A. dividends
- Dividend yield
- 1.19%
- Forward dividend
- 1.20 EUR
- Payout ratio
- 48.0%
- Ex-dividend date
- May 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 9.59M | 1.00 | 48.0% |
| 2024 | EUR 8.17M | 0.85 | 49.2% |
| 2023 | EUR 7.71M | 0.80 | 60.1% |
| 2022 | EUR 6.85M | 0.71 | 45.5% |
| 2021 | EUR 6.49M | 0.67 | 47.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns PHARMANUTRA S.P.A.
- Insiders 65.02%
- Institutions 15.00%
- Public & others 19.97%
- Shares outstanding 9.58M
- Free float 3.24M
PHARMANUTRA S.P.A. company profile
- Company name
- PHARMANUTRA S.P.A.
- Ticker
- 761.F
- ISIN
- IT0005274094
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 128
- Fiscal year end
- December
- Address
- Via Campodavela 1, Pisa, PI, Italy, 56122
- Phone
- 39 05 07 84 65 00
- Website
- pharmanutra.it
About PHARMANUTRA S.P.A.
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports. The company also sells instrumentation and software for body bioimpedance analysis through agents, distributors, and online sales. Pharmanutra S.p.A. was founded in 2000 and is headquartered in Pisa, Italy.
PHARMANUTRA S.P.A. management
4- Mr. Andrea LacorteFounder, Chairman & Executive Director · born 1960
- Mr. Roberto LacorteCo-Founder, MD, Vice Chairman & Executive Director · born 1968
- Mr. Carlo VolpiDelegate Advisor, COO & Executive Director
- Mr. Germano TarantinoScientific Director & Executive Director · born 1979